Apriori Bio’s AI Platform Provides Variant-Proof Protection from Viral Threats


Following more than two years of development, Flagship Pioneering unveils Apriori Bio with $50 million of committed capital. Flagship Pioneering announced the launch of Apriori Bio, a health security company providing variant-proof protection against rapidly evolving viruses.

Apriori has developed Octavia, a unique biology-informed AI platform that can infer the full landscape of potential variants for a given virus. Using Octavia, Apriori can define the antibody repertoire that most broadly protects against current and future virus variants, enabling the development of variant-proof vaccines and antibody drugs.

Read more about this news here.

Related articles

Recent articles